Clinical study of mesenchymal stem cell extracellular vesicles in the treatment of acute myocardial infarction

country:China
industry field:Biological medicine
release unit:河北医科大学第二医院
demand unit:The Second Hospital of Hebei Medical University
cooperation mode:unlimited
2023-06-06 18:16:28 16
Project description
(1) Evaluate the safety of mesenchymal stem cell extracellular vesicle therapy in patients with acute myocardial infarction (2) Evaluate the effectiveness of mesenchymal stem cell extracellular vesicle therapy in patients with acute myocardial infarction and explore its possible mechanisms of action. Myocardial infarction (AMI) is one of the major fatal diseases of cardiovascular disease in China, and its incidence rate is on the rise. Myocardial infarction (AMI) is one of the major fatal diseases of cardiovascular disease in China, and its incidence rate is on the rise. With the implementation of the "China AMI Standardized Treatment Project", the mortality rate of AMI in China has decreased from around 8% to around 3.8%. Nevertheless, the incidence of heart failure after AMI remains high. The loss of functional myocardial cells and the limited proliferation and differentiation ability of remaining myocardial tissue are important pathological foundations for irreversible damage to cardiac structure and function caused by AMI. Therefore, how to achieve myocardial regeneration and repair after infarction is an urgent issue that needs to be addressed at this stage. As an important tool for information exchange between cells, stem cell derived exosomes participate in the repair of damaged myocardium after AMI, promote angiogenesis, inhibit myocardial fibrosis, and can significantly reduce the size of myocardial infarction and improve cardiac function. However, stem cell derived exosomes are still in the preclinical research stage, and there are no clinical studies on the treatment of myocardial infarction with exosomes. This study selected patients who received PCI treatment within one month after myocardial infarction in our hospital and received continuous treatment with stem cell derived extracellular vesicles for four weeks. They were followed up for observation, and underwent cardiac ultrasound, blood biochemistry, and other examinations before treatment, 1 month, 3 months, 6 months, and 1 year of treatment to observe their safety, observe their impact on cardiac function, and explore their possible mechanisms of action, in order to find effective methods for damaged myocardial regeneration and repair.

contact:

contact information:

company address:河北省石家庄市和平西路215号

Company profile:河北医科大学第二医院前身为1918年1月成立的直隶公立医学专门学校附设诊所,1920年扩建为医院,1958年迁至石家庄市,2013年设立东院区,北院区、西山医养一体化医院、正定新区医院正在建设中。目前,医院已成为河北省最大的一所集医疗、教学、科研、保健、康复、急救为一体的综合性三级甲等医院。为亚洲国际救援会员单位、国家级爱婴医院、首批全国百姓放心示范医院;国家药物临床试验机构,卫生部腔镜培训基地,卫生部冠心病介入治疗培训基地,中华医学会腹腔镜内镜学培训基地,河北省神经内科、麻醉、急诊、影像、核医学、检验、护理、病历等多个省级质量控制中心所在单位。医院编制床位2816张,2015年门急诊总量217万人次,出院病人13万人次,手术26661例。医院人才济济,技术力量雄厚。拥有中国工程院院士1人、河北省高端人才1人,博士生导师25人,享受国务院特殊津贴专家、省管专家、省有突出贡献中青年专家59人。医院科室专业齐全,综合实力居全省首位,其中心血管内科、心脏大血管外科、神经内科、眼科、呼吸内科、急诊科、麻醉科和临床护理专业为国家重点临床专科;内科学为河北省强势特色学科(群);内科学、外科学、神经内科学为省级重点学科;神经内科、心血管内科、消化内科、血液内科、呼吸内科、泌尿外科、眼科、妇产科、神经外科、心血管外科、小儿外科、耳鼻喉科、普外科、病理科、医学影像科为省级医学重点学科;急诊科为省级医学重点发展学科。医院多数临床科室为省内学术牵头单位,每年主办、承办国际、国内、省内等大型高层次学术会议交流40余次。医院每年开展多项国内外领先技术疗法。其中经前臂动脉微创化冠脉介入治疗技术,心脏冠脉搭桥技术,器官移植技术,造血干细胞移植技术,“体外受精、胚胎移植”技术,肿瘤生物治疗技术等达到国内先进水平。医院高度重视医学科技研究。拥有河北省心脑血管病研究所、呼吸病研究所、消化病研究所、血液病研究所等21个医学研究所、中心、室。临床神经病学实验室为省部共建重点实验室,神经病学、消化病学、血液病学、血管稳态实验室为省级重点实验室。河北省心脑血管病协同防治中心是省内医疗系统唯一建设于医院的中心。近年来,医院承担国家自然基金项目36项,国家863子课题3项, “十二五” 国家科技支撑计划子课题8项;荣获国家科技进步二等奖1项、河北省科技进步一等奖5项、二等奖9项、三等奖57项。医院为河北医科大学第二临床医学院, 16个专业为博士学位培养点,33个专业为硕士学位培养点;拥有6项省级精品课程;每年在院学生近2000名,其中博士、硕士研究生近1000名。医院以严控基础质量为立院之本,实现了全程、全员医疗质量控制管理。积极创新医疗服务模式,在省内率先开通一站式预约诊疗中心、肿瘤诊疗会诊中心、院内会诊系统等,全年365天开诊、急诊24小时接待患者,良好的行业作风、优秀的人才队伍、精湛的医疗技术、现代化的医疗设备及人性化服务得到了社会各界的广泛赞誉

  • 2022-11-02 18:02 *** 电话联系了该立项企业
  • 2022-11-02 18:02 *** 电话联系了该立项企业
  • 2022-11-02 18:02 *** 电话联系了该立项企业
  • 2022-11-02 18:02 *** 电话联系了该立项企业
  • 2022-11-02 18:02 *** 电话联系了该立项企业
related item
Drug development of oral GnRH receptor antagonist

country:China

release time:2023-07-12

release unit:石家庄以岭药业股份有限公司

core technology:Development of oral GnRH

demand unit:Shijiazhuang Yiling Pharmaceutical Co., Ltd

cooperation mode:Project cooperation

participate in the project
Inheriting the Circuit Park Project

country:No limit

release time:2023-06-06

release unit:河北寰球才智网

core technology:Inheriting the Circuit Park Project

demand unit:Guozhi Technology (Hebei) Co., Ltd

cooperation mode:unlimited

participate in the project
The latest international technology of high-speed steel

country:China

release time:2023-06-06

release unit:河北挚诚莱皓科技服务有限公司

demand unit:Hebei Zhicheng Laihao Technology Service Co., Ltd

cooperation mode:unlimited

participate in the project
Transformation and Upgrade Projects for Traditional Musical Instrument Manufacturing Enterprises in the 5G Era

country:China

release time:2023-06-06

release unit:武强嘉华乐器有限公司

core technology:Musical Instrument Manufacturing and Research and Development

demand unit:Wuqiang Jiahua Musical Instrument Co. Ltd

cooperation mode:Project cooperation

participate in the project
Hebei Global Intelligence Information
X
Hello! Hebei Huanqiu Intelligence Network Customer Service Xiaohui will serve you wholeheartedly~
You can leave questions and contact information, and special personnel will contact you~
name *
telephone *
problem *
Thank you for your message~ Close the window